141 related articles for article (PubMed ID: 20543711)
1. Neuropeptide Y receptor Y2 gene polymorphism interacts with plasma neuropeptide Y levels in predicting left ventricular hypertrophy in dialysis patients.
Testa A; Mallamaci F; Macrì R; Pisano A; Spoto B; Malatino LS; Stancanelli B; Tripepi G; Benedetto FA; Zoccali C
J Hypertens; 2010 Aug; 28(8):1745-51. PubMed ID: 20543711
[TBL] [Abstract][Full Text] [Related]
2. Plasma neuropeptide Y immunoreactivity influences left ventricular mass in pheochromocytoma.
Kuch-Wocial A; Slubowska K; Kostrubiec M; Pasierski T; Januszewicz W; Switalska H; Wocial B; Pruszczyk P
Clin Chim Acta; 2004 Jul; 345(1-2):43-7. PubMed ID: 15193976
[TBL] [Abstract][Full Text] [Related]
3. Association of interleukin-6 -174G/C promoter polymorphism with hypertension and left ventricular hypertrophy in dialysis patients.
Losito A; Kalidas K; Santoni S; Jeffery S
Kidney Int; 2003 Aug; 64(2):616-22. PubMed ID: 12846758
[TBL] [Abstract][Full Text] [Related]
4. Neuropeptide Y and markers of osteoblast activity in dialysis patients: a cross-sectional study.
Panuccio V; Cutrupi S; Pizzini P; Mallamaci F; Tripepi G; Zoccali C
Am J Kidney Dis; 2007 Dec; 50(6):1001-8. PubMed ID: 18037100
[TBL] [Abstract][Full Text] [Related]
5. Modulation of contractile function through neuropeptide Y receptors during development of cardiomyocyte hypertrophy.
Allen AR; Kelso EJ; Bell D; Zhao Y; Dickson P; McDermott BJ
J Pharmacol Exp Ther; 2006 Dec; 319(3):1286-96. PubMed ID: 16973886
[TBL] [Abstract][Full Text] [Related]
6. Vitamin D receptor (VDR) gene polymorphism is associated with left ventricular (LV) mass and predicts left ventricular hypertrophy (LVH) progression in end-stage renal disease (ESRD) patients.
Testa A; Mallamaci F; Benedetto FA; Pisano A; Tripepi G; Malatino L; Thadhani R; Zoccali C
J Bone Miner Res; 2010 Feb; 25(2):313-9. PubMed ID: 20422622
[TBL] [Abstract][Full Text] [Related]
7. Renal and cardiac neuropeptide Y and NPY receptors in a rat model of congestive heart failure.
Callanan EY; Lee EW; Tilan JU; Winaver J; Haramati A; Mulroney SE; Zukowska Z
Am J Physiol Renal Physiol; 2007 Dec; 293(6):F1811-7. PubMed ID: 17804485
[TBL] [Abstract][Full Text] [Related]
8. Can angiotensin II +1675 G/A type 2 receptor gene polymorphism be a marker of left ventricular hypertrophy in patients with aortic stenosis?
Orlowska-Baranowska E; Placha G; Baranowski R; Michalek P; Gora J; Gaciong Z; Stepinska J
J Heart Valve Dis; 2007 Sep; 16(5):495-503. PubMed ID: 17944121
[TBL] [Abstract][Full Text] [Related]
9. Neuropeptide Y gene polymorphism and plasma neuropeptide Y level in febrile seizure patients in Taiwan.
Lin LC; Lin HS; Yang RC
Kaohsiung J Med Sci; 2007 Nov; 23(11):560-5. PubMed ID: 18055304
[TBL] [Abstract][Full Text] [Related]
10. Neuropeptide Y, left ventricular mass and function in patients with end stage renal disease.
Zoccali C; Mallamaci F; Tripepi G; Benedetto FA; Parlongo S; Cutrupi S; Bonanno G; Rapisarda F; Fatuzzo P; Seminara G; Cataliotti A; Malatino LS
J Hypertens; 2003 Jul; 21(7):1355-62. PubMed ID: 12817184
[TBL] [Abstract][Full Text] [Related]
11. Inflammation, residual kidney function, and cardiac hypertrophy are interrelated and combine adversely to enhance mortality and cardiovascular death risk of peritoneal dialysis patients.
Wang AY; Wang M; Woo J; Lam CW; Lui SF; Li PK; Sanderson JE
J Am Soc Nephrol; 2004 Aug; 15(8):2186-94. PubMed ID: 15284304
[TBL] [Abstract][Full Text] [Related]
12. The long-term behavior and predictors of left ventricular hypertrophy in hemodialysis patients.
Kutlay S; Dincer I; Sengül S; Nergizoglu G; Duman N; Ertürk S
Am J Kidney Dis; 2006 Mar; 47(3):485-92. PubMed ID: 16490628
[TBL] [Abstract][Full Text] [Related]
13. Association of insulin-like growth factor-1 receptor gene polymorphisms with left ventricular mass and geometry in essential hypertension.
Horio T; Kamide K; Takiuchi S; Yoshii M; Miwa Y; Matayoshi T; Yoshihara F; Nakamura S; Tokudome T; Miyata T; Kawano Y
J Hum Hypertens; 2010 May; 24(5):320-6. PubMed ID: 19759555
[TBL] [Abstract][Full Text] [Related]
14. Renal function dependent association of AGTR1 polymorphism (A1166C) and electrocardiographic left-ventricular hypertrophy.
Smilde TD; Zuurman MW; Hillege HL; van Veldhuisen DJ; van Gilst WH; van der Steege G; Voors AA; Kors JA; de Jong PE; Navis G
Am J Hypertens; 2007 Oct; 20(10):1097-103. PubMed ID: 17903694
[TBL] [Abstract][Full Text] [Related]
15. Long-term evolution and changing associations of left ventricular hypertrophy after starting hemodialysis.
Takeda A; Toda T; Iwamoto H; Watanabe K; Matsui N
Nephron Clin Pract; 2008; 110(2):c126-32. PubMed ID: 18931516
[TBL] [Abstract][Full Text] [Related]
16. Association between cardiovascular autonomic neuropathy and left ventricular hypertrophy in diabetic haemodialysis patients.
Nishimura M; Hashimoto T; Kobayashi H; Fukuda T; Okino K; Yamamoto N; Nakamura N; Yoshikawa T; Takahashi H; Ono T
Nephrol Dial Transplant; 2004 Oct; 19(10):2532-8. PubMed ID: 15252162
[TBL] [Abstract][Full Text] [Related]
17. Leu7Pro polymorphism in the neuropeptide Y (NPY) gene is associated with impaired glucose tolerance and type 2 diabetes in Swedish men.
Nordman S; Ding B; Ostenson CG; Kärvestedt L; Brismar K; Efendic S; Gu HF
Exp Clin Endocrinol Diabetes; 2005 May; 113(5):282-7. PubMed ID: 15926114
[TBL] [Abstract][Full Text] [Related]
18. Neuropeptide Y suppresses absence seizures in a genetic rat model primarily through effects on Y receptors.
Morris MJ; Gannan E; Stroud LM; Beck-Sickinger AG; O'Brien TJ
Eur J Neurosci; 2007 Feb; 25(4):1136-43. PubMed ID: 17331209
[TBL] [Abstract][Full Text] [Related]
19. Role of candidate modifier genes on the phenotypic expression of hypertrophy in patients with hypertrophic cardiomyopathy.
Brugada R; Kelsey W; Lechin M; Zhao G; Yu QT; Zoghbi W; Quinones M; Elstein E; Omran A; Rakowski H; Wigle D; Liew CC; Sole M; Roberts R; Marian AJ
J Investig Med; 1997 Dec; 45(9):542-51. PubMed ID: 9444881
[TBL] [Abstract][Full Text] [Related]
20. Vascular neuropeptide Y Y1-receptors in the rat kidney: vasoconstrictor effects and expression of Y1-receptor mRNA.
Modin A; Malmström RE; Meister B
Neuropeptides; 1999 Aug; 33(4):253-9. PubMed ID: 10657500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
